# Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients

> **NCT01925209** · PHASE2,PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 251 (actual)

## Conditions studied

- Sporadic Inclusion Body Myositis

## Interventions

- **DRUG:** BYM338/bimagrumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01925209
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-26
- **Primary completion:** 2016-01-06
- **Final completion:** 2016-01-06
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01925209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01925209, "Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01925209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*